Stock Events

Stock Events

Alector 

€2.24
41
+€0.07+3.04% Today

Statistics

Day High
2.27
Day Low
2.17
52W High
2.78
52W Low
0.89
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2025
Next
Next
-0.32
-0.28
-0.24
-0.21
Expected EPS
-0.20873919400000002
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0Z2.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurodegenerative diseases, directly competing with Alector's Alzheimer's and dementia treatments.
Anavex Life Sciences
AVXL
Mkt Cap307.67M
Anavex Life Sciences works on treatments for Alzheimer's disease, directly competing with Alector's pipeline.
AC Immune SA
ACIU
Mkt Cap303.29M
AC Immune develops precision medicine for neurodegenerative diseases, including Alzheimer's, similar to Alector's focus.
Prothena
PRTA
Mkt Cap580.86M
Prothena Corporation focuses on therapies for neurodegenerative diseases, closely competing with Alector's portfolio.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals develops drugs for neurological disorders, competing in the same space as Alector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, including neurodegenerative disorders, competing with Alector.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing for various diseases, including potential treatments for neurodegenerative diseases, indirectly competing with Alector.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, including a focus on genetic therapies that could address neurodegenerative diseases, indirectly competing with Alector.
Novartis
NVS
Mkt Cap279.67B
Novartis AG, a large pharmaceutical company, has a broad portfolio that includes treatments for neurodegenerative diseases, making it a competitor in the same therapeutic area as Alector.

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Arnon Rosenthal Ph.D.
Employees
175
Country
United States
ISIN
US0144421072

Listings

MU
DE
0Z2.MU
STU
DE
0Z2.STU
XNAS
US
ALEC
BOATS
BOATS
ALEC.BOATS

0 Comments

Share your thoughts

FAQ

What is Alector stock price today?▼
The current price of 0Z2.STU is €2.24 EUR — it has increased by +3.04% in the past 24 hours. Watch Alector stock price performance more closely on the chart.
What is Alector stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alector stocks are traded under the ticker 0Z2.STU.
Is Alector stock price growing?▼
0Z2.STU stock has risen by +15.12% compared to the previous week, the month change is a +7.6% rise, over the last year Alector has showed a +144.59% increase.
When is the next Alector earnings date?▼
Alector is going to release the next earnings report on July 30, 2026.
How many employees does Alector have?▼
As of May 06, 2026, the company has 175 employees.
In which sector is Alector located?▼
Alector operates in the Health & Wellness sector.
When did Alector complete a stock split?▼
Alector has not had any recent stock splits.
Where is Alector headquartered?▼
Alector is headquartered in South San Francisco, United States.